Centro De Ingenieria Genetica Y Biotecnologia

Centro De Ingenieria Genetica Y Biotechnologia

Centro De Ingenieria Genetica Biotecnolgia

Hilda Elisa Garay Pérez

Osvaldo Reyes Acosta

Glay Chinea Santiago

Osmany Guirola Cruz

Vivian Huerta Galindo

Mónica Sarría Núñez

Alexis Musacchio Lasa

Boris Ernesto Acevedo Castro

Gerardo Enrique Guillén Nieto

Luis Javier González López

Raimundo Ubieta Gómez

Maribel Guerra Vallespi

Noralvis Fleitas Salazar

Alejandro Miguel Martin Dunn

Patricia Gabriela Toledo Mayora

Ernesto Lopez Mola

Viviana Falcón Cama

Olvaldo Reyes Acosta

Anìa Cabrales Rico

Isis Del Carmen Torréns Madrazo

Sonia Gonzalez Blanco

Alejandro Miguel Martín Dunn

Eduardo Martínez Diaz

Dianne Pupo Gómez

Alexis Yero Díaz

Gabriel Jesús Márquez Perera

Rocío Garateix Suárez

Karen Alvarez Pérez

Sonia González Blanco

Mariela Vázquez Castillo

María Del Carmen Abrahantes Pérez

Cruz Matilde Lopez Abad

Viviana FalcÓn Cama

Mónica SARRÍA NÚÑEZ

Mariela VÁZQUEZ Castillo

Rocio Garateix SUÁREZ

Gabriel Jesús MÁRQUEZ Perera

Dianne Pupo GÓMEZ

Alexis Yero DÍAZ

Karen Alvarez PÉREZ

The present invention discloses structurally constrained synthetic peptides that have been optimized for the formation of a beta hairpin structure. Said peptides are able to inhibit or attenuate Dengue virus (DENV) infections. The invention also discloses pharmaceutical compositions containing these synthetic peptides, which are useful for the prevention and/or treatment of DENV-caused infections. Likewise, the invention disclosed a method for treating infections caused by this virus.

Beta hairpin peptides having antiviral properties against Dengue virus

The present invention comprises cyclic peptides bearing antitumor and antiangiogenic properties, as well as their corresponding pharmaceutically-suitable salts and also pharmaceutical compositions containing it. These cyclic peptides are used to prepare medicines for human and/or veterinary therapeutics, and additionally in diagnosis. These compounds can be used to detect, monitor and/or control a range of cellular proliferation-related disorders, such as oncological diseases and undesired angiogenesis. Moreover, they can be included as part of controlled release systems, and used more precisely in the field of nanobiotechnology, either because of their self-assembly capacity or as part of other systems.

Cyclic peptides with an anti-neoplasic and anti-angiogenic activity

The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family.

Chimerical peptidic molecules with antiviral properties against the viruses of the Flaviviridae family

The present invention is related to the development of peptides derived from the sequence HYRIKPTFRRLKWKYKGKFW (SEQ ID NO.: 13), showing amino acid substitutions, these peptides unable to bind to the lipopolysaccharides and bearing anti-tumoral and immunomodulatory capacities. These peptides alone or in combination are useful to treat cancer, and also in synergy with conventional therapies.

Immunomodulatory and anti-tumour peptides

Growing community of inventors

Havana, Cuba

Hilda Elisa Garay Pérez